Objective To systematically evaluate the efficacy and safety of Shugan Jieyu Capsules in the treatment of female depression. Methods In PubMed, Cochrane Library, EMBASE, APA Psyclnfo, China Biomedical Literature Service System, China Knowledge Network, Wipro and Wanfang databases, randomized controlled trials(RCTs) of Shugan Jieyu Capsules for the treatment of female depression published by March 31, 2024 were searched, and RevMan 5.4 software was used for the included Meta-analysis of the studies was performed. Results 21 clinical studies and a total volume of 1783 patients were ultimately included in this study. Analysis results showed that, in terms of reducing HAMD scores on female depression, the administration of Shugan Jieyu Capsules in combination with antidepressant chemical was superior to the administration of antidepressant chemical alone(SMD=-0.87, 95%CI[-1.17,-0.57], P<0.01), the administration of Shugan Jieyu Capsules alone was superior to the administration of antidepressant chemical alone for female depression(SMD=-0.44, 95%CI[-0.84,-0.04], P=0.03).For postpartum depression(PPD) and perimenopausal depression(PMD) patients, Shugan Jieyu capsule combined with antidepressants was superior to antidepressants alone in reducing HAMD scores(SMD=-0.86,95%CI[-1.49,-0.22],P=0.008;SMD=-1.02,95%CI[-1.57,-0.47],P=0.000 3). In terms of reducing HAMA scores, the administration of Shugan Jieyu Capsules in combination with antidepressant chemical was superior to the administration of antidepressant chemical alone(MD=-1.19, 95%CI[-2.22,-0.16], P=0.02), the administration of Shugan Jieyu Capsules alone was superior to the administration of Sertraline Hydrochloride alone, but comparable to that of Paroxetine. For patients with Postpartum Depression(PPD) or Perimenopausal Depression(PMD), in terms of reducing HAMD scores, the administration of Shugan Jieyu Capsules in combination with antidepressant chemical was superior to the administration of antidepressant chemical alone(P<0.01). there="" was="" no="" statistical="" significance="" in="" the="" difference="" of="" efficacy="" between="" administration="" shugan="" jieyu="" capsules="" alone="" and="" antidepressant="" p="">0.05). In terms of Adverse Events(AEs), the administration of Shugan Jieyu Capsules in combination with antidepressant chemical would not increase the incidence of AEs. The incidence of AEs with the administration of Shugan Jieyu Capsules was lower than that with the administration of antidepressant chemical alone. Conclusion The studies demonstrate that Shugan Jieyu Capsules is effective and safe for treating female depression, and can be used in special periods of female depression, such as postpartum and perimenopausal period. The combination of Shugan Jieyu Capsules and antidepressants is superior to antidepressants alone.

The clinical data of 3 patients with primary rib Langerhans cell histiocytosis(RLCH) were reported and the literature was reviewed.

This paper reports the clinical data of a case of acute myeloid leukemia complicated with Guillain-Barré syndrome and reviews the literature to explore the potential relationship between the two diseases.

Dropped head syndrome(DHS), an age-related rare disease with unique symptoms and medical history, mainly manifested by cervical flexion and chin-chest distortion after a few minutes in the natural position, which seriously affects the patient's appearance and quality of life. However, due to the limited understanding of this disease, the etiology and its complete pathogenesis have not been defined, and no specific treatment method for this disease has appeared in clinical practice. This paper summarizes the etiology, classification and current diagnostic diagnosis and treatment methods in order to provide some reference for the prevention and treatment of DHS.

Neonatal hypoxic-ischemic encephalopathy(HIE) is a common neonatal disease with high rates of disability and mortality, lacking specific therapeutic approaches. The critical mechanism of HIE involves oxidative stress induced by the excessive generation of reactive oxygen species(ROS) and diminished antioxidant capacity. Ferroptosis, a form of programmed cell death triggered by iron-dependent lipid peroxidation and ROS accumulation, plays a significant role in the development of HIE. Nuclear factor E2-related factor 2(NRF2) is the main regulator of oxidative stress response in humans, and extensive studies have shown that NRF2 regulates a variety of genes related to brain iron metabolism and ferroptosis, suggesting its potential to inhibit iron-induced cell death in HIE. Therefore, this review focuses on the protective role of NRF2 in HIE by elucidating the interplay among ferroptosis, HIE, and NRF2